机构：[1]Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and the Collaborative Innovation Center for Biotherapy, 610041 Chengdu, China四川大学华西医院[2]Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, and the Collaborative Innovation Center for Biotherapy, 610041 Chengdu, China四川大学华西医院[3]Department of Cell Biology, and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, 310058 Zhejiang, China浙江大学医学院附属第一医院[4]Institute of Hematology, Zhejiang University & Laboratory of Stem cell and Immunotherapy Engineering, 310058 Zhejing, China[5]State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, 200032 Shanghai, China[6]CARsgen Therapeutics, 200032 Shanghai, China[7]Molecular & Immunological Department, Biotherapeutic Department, Chinese PLA General Hospital, No. 28 Fuxing Road, 100853 Beijing, China
T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.
基金：
This work was supported by the National Key Research and Development Program of
China (2016YFC1303403), the National Natural and Scientific Foundation of China
(81572981/H1611 and 81672397/H1617), the National High-Tech R&D Program (863
Program; 2014AA020704), and the Science and Technology Major Project of Sichuan
Province of China (2017SZDZX0012).
第一作者机构：[1]Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and the Collaborative Innovation Center for Biotherapy, 610041 Chengdu, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Dan Li,Xue Li,Wei-Lin Zhou,et al.Genetically engineered T cells for cancer immunotherapy[J].Signal transduction and targeted therapy.2019,4(1):35.doi:10.1038/s41392-019-0070-9.
APA：
Dan Li,Xue Li,Wei-Lin Zhou,Yong Huang,Xiao Liang...&Wei Wang.(2019).Genetically engineered T cells for cancer immunotherapy.Signal transduction and targeted therapy,4,(1)
MLA：
Dan Li,et al."Genetically engineered T cells for cancer immunotherapy".Signal transduction and targeted therapy 4..1(2019):35
医学